Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Acyclic nitrogen double bonded to acyclic nitrogen – acyclic...
Reexamination Certificate
2004-10-21
2010-02-23
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Acyclic nitrogen double bonded to acyclic nitrogen, acyclic...
C514S381000, C534S775000, C548S253000
Reexamination Certificate
active
07666857
ABSTRACT:
An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one.
REFERENCES:
patent: 851444 (1907-04-01), Shulthess
patent: 2950273 (1960-08-01), Pelz
patent: 3366619 (1968-01-01), DeLucia
patent: 4435417 (1984-03-01), Toja et al.
patent: 4510149 (1985-04-01), Cozzi et al.
patent: 4880788 (1989-11-01), Moake et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 5326776 (1994-07-01), Winn et al.
patent: 5482546 (1996-01-01), Eida et al.
patent: 5532202 (1996-07-01), Yoshida
patent: 5622818 (1997-04-01), Kapp et al.
patent: 5669967 (1997-09-01), Hays
patent: 5746821 (1998-05-01), Hays
patent: 5760038 (1998-06-01), Murugesan et al.
patent: 5932546 (1999-08-01), Barrett et al.
patent: 6214813 (2001-04-01), Zhang et al.
patent: 6238442 (2001-05-01), Schumacher et al.
patent: 6248871 (2001-06-01), Ebenezer et al.
patent: 6280959 (2001-08-01), Gleason et al.
patent: 6436915 (2002-08-01), Zhang et al.
patent: 2003/0060453 (2003-03-01), Zhang et al.
patent: 2004/0063764 (2004-04-01), Takemoto et al.
patent: 2004/0082626 (2004-04-01), Takemoto et al.
patent: 2007/0105824 (2007-05-01), Erickson-Miller et al.
patent: 193350 (1904-11-01), None
patent: 0 638 617 (1994-08-01), None
patent: 1 207 155 (2000-07-01), None
patent: 1 253 142 (2001-01-01), None
patent: 1 104 674 (2001-06-01), None
patent: 826207 (1956-07-01), None
patent: 779 880 (1957-07-01), None
patent: 2002-371213 (2002-12-01), None
patent: WO 93/17681 (1993-09-01), None
patent: WO 94/26709 (1994-11-01), None
patent: WO 96/40750 (1996-12-01), None
patent: WO 98/46606 (1998-10-01), None
patent: WO 99/11262 (1999-03-01), None
patent: WO 99/15500 (1999-04-01), None
patent: WO 00/35446 (2000-06-01), None
patent: WO 01/77080 (2001-01-01), None
patent: WO 01/07423 (2001-02-01), None
patent: WO 01/17349 (2001-03-01), None
patent: WO 01/21180 (2001-03-01), None
patent: WO 01/34585 (2001-05-01), None
patent: WO 01/89457 (2001-11-01), None
patent: WO 02/59099 (2002-01-01), None
patent: WO 02/59100 (2002-01-01), None
patent: WO 02/49413 (2002-06-01), None
patent: WO 02/057300 (2002-07-01), None
patent: WO 02/085343 (2002-10-01), None
patent: WO 03/045379 (2003-06-01), None
patent: WO03/074550 (2003-09-01), None
patent: WO03/098992 (2003-12-01), None
patent: WO 03/103686 (2003-12-01), None
patent: WO 2004/054515 (2004-07-01), None
patent: WO 2005/041867 (2005-05-01), None
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 66(1), 1-18, 1977.
Meade et al., “Biochemical Pharmacology of Platelet-Acitvating Factor (and PAF Antagonists) in Relation to Clinical and Experimental Thrombocytopenia”, Biochemical Pharmacology, 41(5), 657-668, 1991.
Gimenez et al., “Effect of CDP-Choline Administration on Brain Striatum Platelet-Activating Factor in Aging Rats”, European Journal of Pharmacology, 344(⅔), 149-152, 1998.
Yilmaz et al., “Intravenous Administration of Choline or CDP-Choline Improves Platelet Count and Platelet Closure Times in Endotoxin-Treated Dogs”, Shock, 25(1), 73-79, 2006.
Yamazaki, et al., Database HCAPLUS, AN 1995: Abstract, 196968.
A. Esteve, Ann. Pharm. Franc., 1950, vol. 8, No. 9-10, pp. 594-604.
Morris, et al., Anti-Cancer Drugs, 1997, vol. 8, No. 8, pp. 746-755.
Bartley, et al., Cell, 1994, vol. 77, pp. 1117-1124.
Olszewski, et al., Database CAPLUS on STN, 1995, Chem. Abstracts, No. 122:81695.
Olszewski, et al., J. Org. Chem., 1994, vol. 59, pp. 4285-4296.
Lamb, et al., Nucleic Acids Research, 1995, vol. 23, No. 16, pp. 3283-3289.
Seidel, et al., Proc. Natl. Acad. Sci. USA, Mar. 1995, vol. 92, pp. 3041-3045.
Berkhout, et al., J. of Biological Chemistry, Jun. 1997, vol. 272, No. 26, pp. 16404-16413.
Vermeulen, et al., Blood, 1998, vol. 92, No. 3, pp. 894-900.
Hasegawa, et al., Int. J. Immunopharmac, 1996, vol. 18, No. 2, pp. 103-112.
Kumamoto, et al., British Journal of Haematology, 1999, vol. 105, pp. 1025-1033.
Shiotsu, et al., Experimental Hematology, 1998, vol. 26, pp. 1195-1201.
Komatsu, et al., Blood, 1996, vol. 87, No. 11, pp. 4552-4560.
Uguccioni, et al., J. Exp. Med., 1996, vol. 183, pp. 2397-2384.
Taylor, et al., J. Org. Chem., 1987, vol. 52, pp. 4107-4110.
Kuter, et al., Seminars in Hematology, Apr. 2000, vol. 37, No. 2, pp. 41-49.
Ballestrero, et al., Oncology, 2000, vol. 59, pp. 7-13.
Sawai, et al., Journal of Leukocyte Biology, Jul. 2000, vol. 68, pp. 137-143.
Vigon, et al., Proc. Natl. Acad. Sci. USA, Jun. 1992, vol. 89, pp. 5640-5644.
Laurenz, et al., Comp. Biochem Physiol., 1997, vol. 116A, No. 4, pp. 369-377.
Metcalf, et al., Nature, Jun. 16, 1994, vol. 369, pp. 519-520.
Bussel, et al., Seminars in Hematology, 2000, vol. 37, pp. 1-49 (Table of Contents).
McDonald, et al., Am. J. of Pediatric Hematology/Oncology, 1992, vol. 14, No. 1, pp. 8-21.
Souyri, et al., Cell, 1990, vol. 63, pp. 1137-1147.
Bazan, et al., Pro. Natl. Acad. Sci. USA, Sep. 1990, vol. 87, pp. 6934-6938.
Sauvage, et al., Nature, Jun. 16, 1994, vol. 369, pp. 533-538.
Wendling, et al., Nature, Jun. 16, 1994, vol. 369, pp. 571-574.
Kaushansky, et al., Nature, Jun. 16, 1994, vol. 369, pp. 568-571.
King, et al., The Journal of Immunology, 2000, pp. 3774-3782.
Kikuta, et al., Experimental Hematology, 2000, vol. 28, pp. 311-317.
Somlo, et al., Blood, May 1, 1992, vol. 93, No. 9, pp. 2798-2806, 1999.
Kirley-Neumann, et al., Cytokines, Cellular & Molecular Therapy, 2000, vol. 6, pp. 47-56.
Egger, et al., Bone Marrow Transplant, 1998, vol. 22, pp. 34-35.
Gaudron, et al., Stem Cells, 1999, vol. 17, pp. 100-106.
Fetscher, et al., Current Opinion in Hematology, 2000, vol. 7, pp. 255-260.
Clemons, et al., Breast Cancer Res. Treatment, 1999, vol. 57, pp. 127.
Greene, “Protective Groups in Organic Synthesis”, 1981, Table of Contents.
Methia, et al., Blood, 1993, vol. 82, No. 5, pp. 1395-1401.
Yamazaki, et al., Japn. J. Toxicol. Environ. Health, 1994, vol. 94, No. 5, pp. 448-453.
Duffin, et al., J. of the Chem. Soc., 1954, pp. 408-441.
King, et al., Scand. J. of Immunol., 1999, vol. 49, No. 2, pp. 184-192.
Konica Corp. Derwent No. 92-077508/10, 1992.
Mitsubishi Pharma Corp. Derwent No. 2003-845201/78, 2003.
Mitsubishi Pharma Corp. Derwent No. 2003-767492/72, 2003.
Balli, et al., Dyes. Pigm., 1981, vol. 2, No. 2, pp. 93-124.
Balli, et al., Justus Liebigs Ann. Chem., 1966, vol. 699, pp. 133-134.
Dziomko, et al., Chem. Heterocycl. Compd., 1984, vol. 20, No. 2, pp. 196-200.
Duffy, et al., J. Med. Chem., 2001, vol. 44, No. 22, p. 3730-3745.
Kimura, et al., FEBS Letters, 1998, vol. 428, No. 3, pp. 250-254.
Beckert, et al., Monatshefte Fur Chemie, 1989, vol. 120, pp. 1125-1137.
A. Esteve, Ann. Pharm. Franc., 1950, vol. 8, No. 9-10.
Minssen-Guette, et al., Bulletin De La Societe Chimique De France, 1968, No. 5, pp. 2106-2110.
European Search report dated Dec. 15, 2003.
European office action dated Feb. 2, 2005.
Bussel, et al., Seminars in Hematology, 2000, vol. 37, pp. 1-49 (whole journal).
Brook Christopher S.
Ping Li-Jen J.
Dustman Wayne J.
Gimmi Edward R.
Kinzig Charles M.
Powers Fiona T
SmithKline Beecham Corp.
LandOfFree
2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221106